All In Biotech

Drug Trial Radar · NCT05912387

Statin Therapy in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study

The Effect of Statin Therapy on Bile Acid Physiology and the Microbiome in Primary Sclerosing Cholangitis (PSC): a Multi-omics Study

Last checked: Nov 20, 2026Latest source record: Feb 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

15

Planned (sponsor's estimate)

Start

May 31, 2023

Primary completion

May 31, 2027

Study completion Dec 31, 2027

Sponsor

Lead sponsor
Stanford UniversityAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 22, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Basic science
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

PSC is a liver disease that has no medical cure. Patients with PSC are at a greatly increased risk of cancer and infection. Additionally, many patients require a liver transplant. Progress towards a cure has been severely limited by an incomplete understanding of why patients develop PSC. The investigators aim to close this gap by conducting a pilot human study in patients with PSC, using statin therapy as a model

Conditions

  • Primary Sclerosing Cholangitis
  • Inflammatory Bowel Diseases

Interventions

  • RosuvastatinDrug

    Rosuvastatin 20 mg tablet once daily by mouth

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in bile acid (BA) profile: total bile acidTime frame: Baseline and week 12
  2. Change in bile acid (BA) profile: secondary bile acids:primary bile acids ratioTime frame: Baseline and week 12
  3. Change in bile acid (BA) profile: conjugated:unconjugated BAs ratioTime frame: Baseline and week 12
  4. Change in pathogen density in the small intestineTime frame: Baseline and week 12
  5. Change in bacterial gene expression profile in the small intestineTime frame: Baseline and week 12

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Stanford University

    Stanford, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.